Want to see DRUG full AI Analyst Report?
DRUG Stock Chart & Stats
$89.90
$0.82(2.04%)
At close: 4:00 PM EST
$89.90
$0.82(2.04%)
Day’s Range― - ―
52-Week Range$25.56 - $123.75
Previous Close$40.4
Volume34.65K
Average Volume (3M)102.09K
Market Cap
$745.00M
Enterprise Value$477.92
Total Cash (Recent Filing)$309.47M
Total Debt (Recent Filing)$82.07K
Price to Earnings (P/E)―
Beta5.53
Next Earnings
Aug 13, 2026EPS Estimate
-1.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.24
Shares Outstanding9,787,161
10 Day Avg. Volume115,326
30 Day Avg. Volume102,086
Financial Highlights & Ratios
PEG Ratio-0.27
Price to Book (P/B)7.08
Price to Sales (P/S)0.00
P/FCF Ratio-66.82
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$182.50Price Target Upside103.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.67
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Large Cash Reserves Provide RunwayA material increase in cash to ~C$309.7M materially extends the company’s ability to fund multiple clinical programs and R&D without immediate financing. This durable liquidity reduces near-term funding pressure, enabling trial execution, partner talks, and strategic option timing over several quarters.
Very Low Financial LeverageExtremely low debt and a substantially enlarged equity base reduce solvency risk and preserve financial flexibility. This balance-sheet structure supports sustained R&D spend and partnering negotiations, lowering bankruptcy risk and enabling non-dilutive strategic choices compared with highly leveraged peers.
Management Alignment And Investor EngagementOption grants and participation at a major healthcare conference signal management incentivization and proactive investor/partner outreach. Long-term equity-based compensation aligns leadership with shareholders and helps sustain focus on clinical milestones and partner deals that materially de-risk programs over 2–6 months.
Bears Say
No Revenue And Widening LossesThe absence of product revenue combined with materially wider net losses is a persistent structural constraint. It forces dependence on capital markets or partnerships to fund operations, increases the probability of dilution, and leaves little operating margin cushion until a program achieves commercialization or a licensing event.
Negative Operating Cash Flow And Rising Cash BurnOperative cash burn has more than doubled year-over-year, creating a durable funding requirement despite current cash balances. Persistent negative operating and free cash flow elevates refinancing or partnership risk and can compel dilutive financings or early licensing if clinical spend remains high.
Negative Return On EquityA materially negative ROE indicates the enlarged equity base is not translating into value creation. Over multiple quarters, negative ROE signals poor capital efficiency and raises questions about shareholder return prospects absent successful clinical progress or monetizable partnerships.
Bright Minds Biosciences News
DRUG FAQ
What was Bright Minds Biosciences’s price range in the past 12 months?
Bright Minds Biosciences lowest stock price was $25.56 and its highest was $123.75 in the past 12 months.
What is Bright Minds Biosciences’s market cap?
Bright Minds Biosciences’s market cap is $745.00M.
When is Bright Minds Biosciences’s upcoming earnings report date?
Bright Minds Biosciences’s upcoming earnings report date is Aug 13, 2026 which is in 24 days.
How were Bright Minds Biosciences’s earnings last quarter?
Bright Minds Biosciences released its earnings results on May 19, 2026. The company reported -$0.793 earnings per share for the quarter, beating the consensus estimate of -$0.863 by $0.07.
Is Bright Minds Biosciences overvalued?
According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued.
Does Bright Minds Biosciences pay dividends?
Bright Minds Biosciences does not currently pay dividends.
What is Bright Minds Biosciences’s EPS estimate?
Bright Minds Biosciences’s EPS estimate is -1.28.
How many shares outstanding does Bright Minds Biosciences have?
Bright Minds Biosciences has 9,787,161 shares outstanding.
What happened to Bright Minds Biosciences’s price movement after its last earnings report?
Bright Minds Biosciences reported an EPS of -$0.793 in its last earnings report, beating expectations of -$0.863. Following the earnings report the stock price went up 11.054%.
Which hedge fund is a major shareholder of Bright Minds Biosciences?
Currently, no hedge funds are holding shares in DRUG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bright Minds Biosciences
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
DRUG Stock 12 Month Forecast
Average Price Target
$182.50
▲(103.00% Upside)
Technical Analysis
Ownership Overview
21.09% Insiders
4.40% Mutual Funds
60.24% Other Institutional Investors
9.26% Public Companies and
Individual Investors